Intuitive Surgical Earnings Call Signals Robust Growth

Intuitive Surgical ((ISRG)) has held its Q1 earnings call. Read on for the main highlights of the call.

Intuitive Surgical’s latest earnings call projected a distinctly upbeat tone, as management highlighted strong growth in revenue and procedures, broad adoption of next-generation systems, and expanding margins. While executives acknowledged regional and policy headwinds, along with cost and cybersecurity risks, they framed these as manageable against a backdrop of robust demand and strengthening clinical evidence.

Strong Top-Line Growth

Intuitive reported total revenue of $2.77 billion, up 23% year over year, or 22% in constant currency, underscoring strong momentum across its portfolio. Recurring revenue grew 23% to $2.4 billion and now accounts for 86% of total sales, reinforcing the company’s high-visibility, annuity-like business model favored by long‑term investors.

Procedure Volume Expansion

Total procedures climbed 17% year over year, with da Vinci procedures rising 16% to 847,000 and Ion procedures jumping 39% to 43,000. U.S. procedures grew 15% while procedures outside the U.S. advanced 20%, indicating that international markets are increasingly important drivers of volume growth.

Product Adoption and System Placements

The company placed 431 da Vinci systems in the quarter, up 17% from a year earlier, including 232 da Vinci 5 systems, 34 SP systems and 34 XiR systems, plus 52 Ion systems. Management also pointed to 119 trade‑ins versus 67 last year, suggesting that the installed base is actively upgrading to new platforms rather than simply expanding in unit count.

da Vinci 5 and Utilization Gains

Adoption of the da Vinci 5 platform is driving higher system utilization, a key metric for returns on capital in hospitals and for Intuitive’s per‑procedure revenue stream. U.S. utilization increased 4%, and da Vinci 5 systems are running at utilization levels about 11% higher than Xi, as the installed base of the new platform approaches 1,500 systems.

Instrument & Service Revenue Strength

Instruments and accessories revenue rose 23% to $1.7 billion, reflecting both higher procedure volumes and richer per‑case economics. Service revenue grew 19% to $434 million, while I&A revenue per da Vinci procedure increased to roughly $1,880 from $1,780, signaling improved monetization of each surgery.

Profitability and Margin Expansion

Non‑GAAP operating margin reached 39%, supported by scale benefits and pricing leverage, while non‑GAAP gross margin improved to 67.8% from 66.4% a year ago. Non‑GAAP net income climbed to $901 million versus $662 million and non‑GAAP EPS rose to $2.50 from $1.81, underscoring that earnings growth is outpacing revenue.

SP and Ion Momentum

Single‑Port procedures surged 68% year over year, with U.S. SP system utilization up 22%, highlighting a fast‑growing niche within the broader robotic surgery portfolio. Ion continued its rapid ramp, with procedure growth of 39%, as hospitals adopt the platform for lung procedures and capitalize on emerging data supporting earlier cancer detection.

Positive Clinical Evidence

Management spotlighted new data from a Mayo Clinic study of 2,115 lesions using Ion, which showed a diagnostic yield of 79% and malignancy sensitivity of 85%. Early‑stage primary lung cancer diagnoses increased from 46% to 69% between 2019 and 2024, with low complication rates, reinforcing the clinical and economic rationale for the platform.

China Market Challenges

China remained a weak spot as procedure growth lagged the corporate average, pressured by low tender activity, pricing policies and intensifying domestic competition. The company does not expect clarity on provincial charge codes and reimbursement until 2027, implying that China will likely remain a drag relative to other regions for several years.

Japan Capital and Short-Term Weakness

In Japan, procedure growth also trailed historical norms after fewer system placements in 2025, pointing to a thinner near‑term capital pipeline. New reimbursement policies were announced and will take effect in 2026, but management stayed cautious given financial constraints at public hospitals that could slow future system adoption.

Bariatric Procedure Decline

The company noted that U.S. da Vinci bariatric procedures declined about 10%, linking the drop to increased use of GLP‑1 drugs for obesity management. While this presents a structural challenge for bariatric volumes, management implied that the broader procedural mix and new indications can offset the pressure over time.

Cybersecurity Incident

Intuitive disclosed a cyber incident in the quarter that led to unauthorized access to some customer and employee data, prompting notifications and remediation efforts. The company emphasized that operations and products were not disrupted and portrayed the event as contained, but it adds another layer of non‑financial risk that investors will monitor.

Input Cost Headwinds and Tariffs

Management warned that higher freight, semiconductor memory and oil‑related material costs, along with tariffs, are set to weigh on margins later in the year. Updated guidance now assumes about a 100‑basis‑point gross margin impact from tariffs alone, suggesting that future margin gains will be harder won despite strong top‑line growth.

Cash and Capital Deployment

Quarter‑end cash and investments fell to $8.0 billion from $9.0 billion, primarily due to $1.1 billion in share repurchases, an acquisition of a distributor in Italy, Spain and Portugal, and $103 million in capital spending. The moves show management leaning into both shareholder returns and strategic expansion in key European markets.

Policy and Reimbursement Uncertainty

Executives flagged potential risks if certain health‑care premium subsidies expire, though they saw no material impact in the quarter. They remain cautious about how policy shifts could influence patient behavior and procedure volumes over time, underscoring that reimbursement and access dynamics remain an external wild card.

Updated Outlook and Forward Guidance

Looking ahead to 2026, Intuitive raised its da Vinci procedure growth outlook to 13.5%–15.5%, reflecting confidence in demand despite regional and policy noise. The company guided to a non‑GAAP gross margin of 67.5%–68.5%, non‑GAAP operating expense growth of 11%–14%, other income of $315 million–$335 million and a tax rate in the low‑20% range, blending robust growth expectations with a realistic view of cost and tariff pressures.

Intuitive Surgical’s earnings call painted the picture of a company balancing powerful growth engines with manageable headwinds, as new systems, rising utilization and strong clinical data drive both revenue and margin expansion. While challenges in China, Japan, bariatrics, costs and cybersecurity will bear watching, the overall message to investors was one of durable demand, widening adoption and confidence in the long‑term trajectory of robotic surgery.